Team

Founder: Dr. Eric Gaucher

Founder Dr. Eric Gaucher

Dr. Gaucher is an Associate Professor at the Georgia Institute of Technology in the Schools of Biology and Chemistry. Prior to joining GT in 2008, Dr. Gaucher was President and researcher of a non-profit scientific research organization that developed nucleic acid-based technology and conducted basic research. Dr. Gaucher’s current research exploits a unique bidirectional approach that combines evolutionary biology and molecular biology. Dr. Gaucher’s laboratory has experience in developing and utilizing evolutionary approaches to better understand the function of biomolecules. This information is then utilized to generate molecules that, in turn, have commercial value. Along these lines, GT has filed a US full patent application for technology discussed in this proposal. As well, Dr. Gaucher has secured more than $400,000 to support the development and growth of General Genomics.

 

 

Lead Scientist: Dr. James Kratzer

Lead Scientist James Kratzer

Dr. Kratzer earned his Ph.D. from Professor Gaucher’s lab in the spring 2013 and is now a full-time employee of General Genomics. Dr. Kratzer has led the development of the uricase research and commercialization project since its inception and he conducted the research associated with the GRA Phase IA and IB programs. Dr. Kratzer has a strong interest in commercialization of intellectual property. Dr. Kratzer has held fellowships from Georgia Tech’s Center for Drug Design, Development and Delivery (CD4) and the Technological Innovation Generating Economic Results (TI:GER) program. In particular, the TI:GER program was an intense two-year training program that taught Dr. Kratzer about commercializing technology but also helped to build-up a network of legal and business contacts that are energized about our intellectual property. Dr. Kratzer has also completed the following Georgia Tech Integrated Program for Startups (GT:IPS) courses: business opportunity, intellectual property, company creation, conflict of interest, SBIR/STTR funding, early-stage funding opportunities for startups.